Delcath Systems (NASDAQ:DCTH) Reaches New 52-Week High – Should You Buy?

Shares of Delcath Systems, Inc. (NASDAQ:DCTH) hit a new 52-week high during trading on Wednesday . The stock traded as high as $17.42 and last traded at $17.22, with a volume of 1228262 shares changing hands. The stock had previously closed at $16.67.

Key Delcath Systems News

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $32 price target while sharply raising its EPS forecasts. The firm now expects a smaller FY2026 loss of $0.17 per share, versus its prior estimate of $0.88, followed by profitability in FY2027 at $0.12 per share. Longer-term estimates were also increased to $0.56 for FY2028, $0.97 for FY2029 and $1.46 for FY2030, suggesting improved confidence in Delcath’s earnings trajectory. MarketBeat analyst estimates
• Positive Sentiment: Zacks highlighted DCTH as a potential momentum stock, citing favorable price momentum and improving earnings-estimate revisions. Another Zacks analysis said Wall Street analysts see potential upside of approximately 42.8%, although price-target projections are not guaranteed. Zacks momentum stock analysis Zacks price target analysis
• Neutral Sentiment: Reported short interest was zero shares both on August 11 and July 27, producing a zero-day short-interest ratio. Because the report also shows an invalid “NaN” change, the data provides no meaningful indication of short-covering or bearish pressure.

Analyst Upgrades and Downgrades

DCTH has been the topic of a number of recent research reports. Zacks Research raised Delcath Systems from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 7th. Wall Street Zen upgraded Delcath Systems from a “hold” rating to a “buy” rating in a report on Saturday. BTIG Research boosted their target price on Delcath Systems from $17.00 to $21.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings reissued a “sell (d+)” rating on shares of Delcath Systems in a research note on Friday. Finally, HC Wainwright restated a “buy” rating and set a $32.00 price target (up from $30.00) on shares of Delcath Systems in a report on Friday. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Delcath Systems presently has an average rating of “Moderate Buy” and an average target price of $23.17.

Delcath Systems Price Performance

The company has a market cap of $597.53 million, a PE ratio of 1,723.72 and a beta of 0.52. The business’s 50 day moving average is $12.61 and its 200-day moving average is $10.97.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.16. Delcath Systems had a net margin of 0.56% and a return on equity of 0.46%. The company had revenue of $29.13 million for the quarter, compared to the consensus estimate of $26.25 million. As a group, sell-side analysts predict that Delcath Systems, Inc. will post -0.17 EPS for the current fiscal year.

Hedge Funds Weigh In On Delcath Systems

Institutional investors and hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp purchased a new position in Delcath Systems in the second quarter valued at $1,362,000. Bank of America Corp DE lifted its holdings in Delcath Systems by 54.0% during the 1st quarter. Bank of America Corp DE now owns 57,729 shares of the company’s stock worth $536,000 after buying an additional 20,249 shares during the last quarter. Royal Bank of Canada lifted its holdings in Delcath Systems by 14.8% during the 1st quarter. Royal Bank of Canada now owns 18,383 shares of the company’s stock worth $170,000 after buying an additional 2,364 shares during the last quarter. Sei Investments Co. lifted its holdings in Delcath Systems by 100.0% during the 1st quarter. Sei Investments Co. now owns 44,058 shares of the company’s stock worth $409,000 after buying an additional 22,029 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC acquired a new position in shares of Delcath Systems during the 1st quarter worth about $306,000. Institutional investors and hedge funds own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.